

16<sup>th</sup> December 2025

**To,**  
**BSE Limited**  
P. J. Towers,  
Dalal Street, Fort,  
Mumbai - 400001  
Security Code: 544442

**Subject: Press Release titled – “Chemkart (India) Limited Clarifies Regulatory Matter; Business Fundamentals Intact”**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time) (“Listing Regulations”), please find enclosed herewith the Press Release titled – “Chemkart (India) Limited Clarifies Regulatory Matter; Business Fundamentals Intact.”

Kindly take the aforesaid information on record.

Thank you.

Yours sincerely,  
For **Chemkart India Ltd**



**Name: Mr. Basavaraj Dalawai**  
**Designation: CFO**  
**Place: Mumbai**



Chemkart (India) Limited

## Chemkart (India) Limited Clarifies Regulatory Matter; Business Fundamentals Intact

**Mumbai, December 16<sup>th</sup>, 2025** - Chemkart India Limited (CIL) is addressing recent media reports and public discourse relating to an investigation initiated by the Directorate of Revenue Intelligence (DRI) concerning certain import transactions of the Company. In the interest of transparency and to ensure that shareholders and stakeholders are accurately informed, the Company provides the following clarification.

The investigation relates to the classification and valuation of select chemical consignments imported during earlier periods, specifically **Instantized Branched Chain Amino Acids (BCAA), Instantized L-Leucine Powder, Instantized L-Isoleucine Powder, and Valine Powder**, over a **relevant five-year period**. As reflected in the table below, aggregate purchases of these products have contributed an average of **approximately 2.8%** to the Company's annual turnover over the last five years, indicating limited revenue dependence on this product category.

From a financial perspective, the total differential customs duty liability for the said five-year period has been assessed at approximately **INR 15.72 crores**. The Company has already discharged **INR 12.78 crores**, demonstrating its intent to resolve the matter promptly and responsibly. The remaining balance of **INR 2.94 crores** is expected to be settled within the next seven days.

For enhanced clarity, the year-wise purchase value of BCAA, Leucine, Iso-Leucine and Valine vis-à-vis the Company's annual turnover for the last five years is summarized below:

Year	Product Purchase (INR Cr)	Annual Turnover (INR Cr)	% of Turnover
FY22	4.65	86.97	5.34%
FY23	3.49	131.00	2.67%
FY24	4.03	132.00	3.05%
FY25	4.94	203.00	2.43%
*FY26	2.56	145.00	1.76%
<b>Total</b>	<b>19.67</b>	<b>697.97</b>	<b>(AVG) - 2.82%</b>

\*Note - FY26 contribution is till 15<sup>th</sup> December 2025

The above table presents a year-wise summary over the last five years, highlighting the purchase value of BCAA, Leucine, Iso-Leucine and Valine in comparison with the Company's annual turnover. As reflected in the data, the contribution of these products to the Company's overall revenue has remained relatively modest, ranging between approximately **1.8% and 5.3%**, with an average contribution of about **2.8% over the five-year period**. The trend also demonstrates a gradual reduction in reliance on these products, thereby lowering concentration risk and exposure.

While the settlement of the duty amount may result in short-term liquidity tightness, management confirms that it does not have any material adverse impact on the Company's ongoing operations, financial stability, or growth plans. Chemkart India Limited continues to witness stable demand across its key segments and remains focused on scaling its value-added nutraceutical offerings and export-oriented manufacturing capabilities.



## Chemkart (India) Limited

The Company reiterates its commitment to high standards of corporate governance, regulatory compliance, and transparent communication with its stakeholders. Chemkart India Limited will continue to keep shareholders appropriately informed of any material developments in line with applicable regulatory requirements.

### About Chemkart (India) Limited

A BSE-listed digital-first company, **Chemkart India Limited** is reimagining the nutraceutical supply chain through vertically integrated operations spanning raw material sourcing to finished formulation manufacturing. The Company leverages strong sourcing intelligence, a global supplier network, and technology-driven processes to ensure quality, traceability, and cost efficiency. With a growing focus on value-added formulations and export-oriented manufacturing, Chemkart aims to build a scalable, compliant, and globally competitive nutraceutical platform.

### Safe Harbour Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labor relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Chemkart (India) Limited	Investor Relations: X-B4 Advisory
CIN : L51220MH2020PLC338631	Name: Rasika Sawant
Email: <a href="mailto:investors@chemkart.com">investors@chemkart.com</a>	Email: <a href="mailto:Rasika@x-b4.com">Rasika@x-b4.com</a>
Tel: + 91 9136383828	Mobile No: +91-9594457518
Website: <a href="http://www.chemkart.com">www.chemkart.com</a>	Website: <a href="http://www.x-b4.com">www.x-b4.com</a>